Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CR1447 in endocrine responsive or TN-AR+ metastatic breast cancer
NCT02067741Phase 2Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jun 2016
- Primary completion
- Aug 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of 4-hydroxytestosterone in breast cancer, sponsored by Swiss Group for Clinical Cancer Research. Started Jun 2016; status: terminated.
02
Drugs
4-hydroxytestosterone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02067741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02067741.